APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Biosimilar Monoclonal Antibodies

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Cancer Biosimilar Monoclonal Antibodies Industry Growth and Trends Forecast to 2032

23 December 2025113 pages

Choose your research edition.

Industry ResearchCancer Biosimilar Monoclonal Antibodies Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Biosimilar Monoclonal Antibodies Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Cancer Biosimilar Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Biosimilar Monoclonal Antibodies Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Biosimilar Monoclonal Antibodies Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

According to APO Research, the global Cancer Biosimilar Monoclonal Antibodies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Cancer Biosimilar Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Cancer Biosimilar Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Biosimilar Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Cancer Biosimilar Monoclonal Antibodies market include Innovent Biologics, Teva Pharmaceutical Industries, Sandoz, Sunshine Guojian, Qilu Pharmaceutical, Merck, Mylan, Roche and Junshi Biosciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Cancer Biosimilar Monoclonal Antibodies market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Cancer Biosimilar Monoclonal Antibodies market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cancer Biosimilar Monoclonal Antibodies market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cancer Biosimilar Monoclonal Antibodies.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Cancer Biosimilar Monoclonal Antibodies market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Cancer Biosimilar Monoclonal Antibodies Market by Company

Innovent Biologics

Teva Pharmaceutical Industries

Sandoz

Sunshine Guojian

Qilu Pharmaceutical

Merck

Mylan

Roche

Junshi Biosciences

Pfizer

Henlius

Biotech Pharma

Bio-Thera Solutions

Amgen

AbbVie

Samsung Bioepis

Celltrion

BristolMyers Squibb

Biocon

Cancer Biosimilar Monoclonal Antibodies Segment by Type

Mouse Derived Monoclonal Antibody

Human Derived Monoclonal Antibody

Human Mouse Chimeric Monoclonal Antibody

Fully Human Derived Monoclonal Antibody

Cancer Biosimilar Monoclonal Antibodies Segment by Application

Hematological System Tumor Treatment

Solid Tumor Treatment

Combination Therapy

Cancer Biosimilar Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Biosimilar Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Biosimilar Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Biosimilar Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Cancer Biosimilar Monoclonal Antibodies companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Cancer Biosimilar Monoclonal Antibodies Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Region (2021-2026) Table 4. Global Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Region (2027-2032) Table 6. Global Cancer Biosimilar Monoclonal Antibodies Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Cancer Biosimilar Monoclonal Antibodies Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Cancer Biosimilar Monoclonal Antibodies Market Size Share by Type (2021-2026) Table 9. Global Cancer Biosimilar Monoclonal Antibodies Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Cancer Biosimilar Monoclonal Antibodies Market Size Share Forecasted by Type (2027-2032) Table 11. North America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Cancer Biosimilar Monoclonal Antibodies Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Cancer Biosimilar Monoclonal Antibodies Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Cancer Biosimilar Monoclonal Antibodies Market Size Share by Application (2021-2026) Table 24. Global Cancer Biosimilar Monoclonal Antibodies Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Cancer Biosimilar Monoclonal Antibodies Market Size Share Forecasted by Application (2027-2032) Table 26. North America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Cancer Biosimilar Monoclonal Antibodies Industry Trends Table 37. Cancer Biosimilar Monoclonal Antibodies Industry Drivers Table 38. Cancer Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges Table 39. Cancer Biosimilar Monoclonal Antibodies Industry Restraints Table 40. Global Cancer Biosimilar Monoclonal Antibodies Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Company (2021-2026) Table 42. Global Cancer Biosimilar Monoclonal Antibodies Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Cancer Biosimilar Monoclonal Antibodies Key Company Headquarters & Area Served Table 44. Global Cancer Biosimilar Monoclonal Antibodies Company, Product Type & Application Table 45. Global Cancer Biosimilar Monoclonal Antibodies Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Cancer Biosimilar Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Innovent Biologics Company Information Table 49. Innovent Biologics Business Overview Table 50. Innovent Biologics Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Innovent Biologics Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 52. Innovent Biologics Recent Development Table 53. Teva Pharmaceutical Industries Company Information Table 54. Teva Pharmaceutical Industries Business Overview Table 55. Teva Pharmaceutical Industries Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Teva Pharmaceutical Industries Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 57. Teva Pharmaceutical Industries Recent Development Table 58. Sandoz Company Information Table 59. Sandoz Business Overview Table 60. Sandoz Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Sandoz Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 62. Sandoz Recent Development Table 63. Sunshine Guojian Company Information Table 64. Sunshine Guojian Business Overview Table 65. Sunshine Guojian Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Sunshine Guojian Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 67. Sunshine Guojian Recent Development Table 68. Qilu Pharmaceutical Company Information Table 69. Qilu Pharmaceutical Business Overview Table 70. Qilu Pharmaceutical Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Qilu Pharmaceutical Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 72. Qilu Pharmaceutical Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Merck Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 77. Merck Recent Development Table 78. Mylan Company Information Table 79. Mylan Business Overview Table 80. Mylan Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Mylan Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 82. Mylan Recent Development Table 83. Roche Company Information Table 84. Roche Business Overview Table 85. Roche Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Roche Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 87. Roche Recent Development Table 88. Junshi Biosciences Company Information Table 89. Junshi Biosciences Business Overview Table 90. Junshi Biosciences Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Junshi Biosciences Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 92. Junshi Biosciences Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Pfizer Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 97. Pfizer Recent Development Table 98. Henlius Company Information Table 99. Henlius Business Overview Table 100. Henlius Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Henlius Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 102. Henlius Recent Development Table 103. Biotech Pharma Company Information Table 104. Biotech Pharma Business Overview Table 105. Biotech Pharma Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Biotech Pharma Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 107. Biotech Pharma Recent Development Table 108. Bio-Thera Solutions Company Information Table 109. Bio-Thera Solutions Business Overview Table 110. Bio-Thera Solutions Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Bio-Thera Solutions Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 112. Bio-Thera Solutions Recent Development Table 113. Amgen Company Information Table 114. Amgen Business Overview Table 115. Amgen Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Amgen Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 117. Amgen Recent Development Table 118. AbbVie Company Information Table 119. AbbVie Business Overview Table 120. AbbVie Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. AbbVie Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 122. AbbVie Recent Development Table 123. Samsung Bioepis Company Information Table 124. Samsung Bioepis Business Overview Table 125. Samsung Bioepis Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Samsung Bioepis Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 127. Samsung Bioepis Recent Development Table 128. Celltrion Company Information Table 129. Celltrion Business Overview Table 130. Celltrion Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Celltrion Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 132. Celltrion Recent Development Table 133. BristolMyers Squibb Company Information Table 134. BristolMyers Squibb Business Overview Table 135. BristolMyers Squibb Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. BristolMyers Squibb Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 137. BristolMyers Squibb Recent Development Table 138. Biocon Company Information Table 139. Biocon Business Overview Table 140. Biocon Cancer Biosimilar Monoclonal Antibodies Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Biocon Cancer Biosimilar Monoclonal Antibodies Product Portfolio Table 142. Biocon Recent Development Table 143. North America Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. North America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 145. North America Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2021-2026) Table 146. North America Cancer Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. North America Cancer Biosimilar Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 148. Europe Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 150. Europe Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2021-2026) Table 151. Europe Cancer Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Europe Cancer Biosimilar Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 153. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 155. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2021-2026) Table 156. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 158. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 160. Latin America Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2021-2026) Table 161. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Latin America Cancer Biosimilar Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 163. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 165. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2021-2026) Table 166. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Cancer Biosimilar Monoclonal Antibodies Product Image Figure 3. Global Cancer Biosimilar Monoclonal Antibodies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Cancer Biosimilar Monoclonal Antibodies Market Size (2021-2032) & (US$ Million) Figure 5. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Region: 2025 VS 2032 Figure 6. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Region (2021-2032) Figure 7. North America Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Mouse Derived Monoclonal Antibody Image Figure 13. Global Mouse Derived Monoclonal Antibody Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Human Derived Monoclonal Antibody Image Figure 15. Global Human Derived Monoclonal Antibody Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Human Mouse Chimeric Monoclonal Antibody Image Figure 17. Global Human Mouse Chimeric Monoclonal Antibody Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Fully Human Derived Monoclonal Antibody Image Figure 19. Global Fully Human Derived Monoclonal Antibody Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Cancer Biosimilar Monoclonal Antibodies Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Type 2025 VS 2032 Figure 22. North America Cancer Biosimilar Monoclonal Antibodies Market Size Share by Type (2021-2032) Figure 23. Europe Cancer Biosimilar Monoclonal Antibodies Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Share by Type (2021-2032) Figure 25. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Cancer Biosimilar Monoclonal Antibodies Market Size Share by Type (2021-2032) Figure 27. Hematological System Tumor Treatment Image Figure 28. Global Hematological System Tumor Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Solid Tumor Treatment Image Figure 30. Global Solid Tumor Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Combination Therapy Image Figure 32. Global Combination Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Cancer Biosimilar Monoclonal Antibodies Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Application 2025 VS 2032 Figure 35. North America Cancer Biosimilar Monoclonal Antibodies Market Size Share by Application (2021-2032) Figure 36. Europe Cancer Biosimilar Monoclonal Antibodies Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Share by Application (2021-2032) Figure 38. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Cancer Biosimilar Monoclonal Antibodies Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Cancer Biosimilar Monoclonal Antibodies Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Cancer Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Cancer Biosimilar Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2021-2032) Figure 45. Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Cancer Biosimilar Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2021-2032) Figure 48. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2021-2032) Figure 51. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Cancer Biosimilar Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2021-2032) Figure 54. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Mouse Derived Monoclonal Antibody
  • Human Derived Monoclonal Antibody
  • Human Mouse Chimeric Monoclonal Antibody
  • Fully Human Derived Monoclonal Antibody
Applications
  • Hematological System Tumor Treatment
  • Solid Tumor Treatment
  • Combination Therapy
Companies covered
  • Innovent Biologics
  • Teva Pharmaceutical Industries
  • Sandoz
  • Sunshine Guojian
  • Qilu Pharmaceutical
  • Merck
  • Mylan
  • Roche
  • Junshi Biosciences
  • Pfizer
  • Henlius
  • Biotech Pharma
  • Bio-Thera Solutions
  • Amgen
  • AbbVie
  • Samsung Bioepis
  • Celltrion
  • BristolMyers Squibb
  • Biocon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Cancer Biosimilar Monoclonal Antibodies Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2021-2032)
  5. 1.4.1 Global Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2021-2026)
  6. 1.4.2 Global Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2027-2032)
  7. 1.5 Key Regions Cancer Biosimilar Monoclonal Antibodies Market Size (2021-2032)
  8. 1.5.1 North America Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (2021-2032)
2 Cancer Biosimilar Monoclonal Antibodies Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Mouse Derived Monoclonal Antibody
  3. 2.1.2 Human Derived Monoclonal Antibody
  4. 2.1.3 Human Mouse Chimeric Monoclonal Antibody
  5. 2.1.4 Fully Human Derived Monoclonal Antibody
  6. 2.2 Global Cancer Biosimilar Monoclonal Antibodies Market Size by Type
  7. 2.2.1 Global Cancer Biosimilar Monoclonal Antibodies Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Cancer Biosimilar Monoclonal Antibodies Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Cancer Biosimilar Monoclonal Antibodies Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Cancer Biosimilar Monoclonal Antibodies Market Size by Regions
  11. 2.3.1 North America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Type (2021-2026)
3 Cancer Biosimilar Monoclonal Antibodies Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hematological System Tumor Treatment
  3. 3.1.2 Solid Tumor Treatment
  4. 3.1.3 Combination Therapy
  5. 3.2 Global Cancer Biosimilar Monoclonal Antibodies Market Size by Application
  6. 3.2.1 Global Cancer Biosimilar Monoclonal Antibodies Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Cancer Biosimilar Monoclonal Antibodies Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Cancer Biosimilar Monoclonal Antibodies Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Cancer Biosimilar Monoclonal Antibodies Market Size by Regions
  10. 3.3.1 North America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Cancer Biosimilar Monoclonal Antibodies Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Cancer Biosimilar Monoclonal Antibodies Industry Trends
  2. 4.2 Cancer Biosimilar Monoclonal Antibodies Industry Drivers
  3. 4.3 Cancer Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges
  4. 4.4 Cancer Biosimilar Monoclonal Antibodies Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Cancer Biosimilar Monoclonal Antibodies Revenue (2021-2026)
  2. 5.2 Global Cancer Biosimilar Monoclonal Antibodies Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Cancer Biosimilar Monoclonal Antibodies Key Company Headquarters & Area Served
  4. 5.4 Global Cancer Biosimilar Monoclonal Antibodies Company, Product Type & Application
  5. 5.5 Global Cancer Biosimilar Monoclonal Antibodies Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Cancer Biosimilar Monoclonal Antibodies Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Cancer Biosimilar Monoclonal Antibodies Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Cancer Biosimilar Monoclonal Antibodies Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Innovent Biologics
  2. 6.1.1 Innovent Biologics Company Information
  3. 6.1.2 Innovent Biologics Business Overview
  4. 6.1.3 Innovent Biologics Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Innovent Biologics Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  6. 6.1.5 Innovent Biologics Recent Developments
  7. 6.2 Teva Pharmaceutical Industries
  8. 6.2.1 Teva Pharmaceutical Industries Company Information
  9. 6.2.2 Teva Pharmaceutical Industries Business Overview
  10. 6.2.3 Teva Pharmaceutical Industries Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Teva Pharmaceutical Industries Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  12. 6.2.5 Teva Pharmaceutical Industries Recent Developments
  13. 6.3 Sandoz
  14. 6.3.1 Sandoz Company Information
  15. 6.3.2 Sandoz Business Overview
  16. 6.3.3 Sandoz Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Sandoz Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  18. 6.3.5 Sandoz Recent Developments
  19. 6.4 Sunshine Guojian
  20. 6.4.1 Sunshine Guojian Company Information
  21. 6.4.2 Sunshine Guojian Business Overview
  22. 6.4.3 Sunshine Guojian Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Sunshine Guojian Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  24. 6.4.5 Sunshine Guojian Recent Developments
  25. 6.5 Qilu Pharmaceutical
  26. 6.5.1 Qilu Pharmaceutical Company Information
  27. 6.5.2 Qilu Pharmaceutical Business Overview
  28. 6.5.3 Qilu Pharmaceutical Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Qilu Pharmaceutical Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  30. 6.5.5 Qilu Pharmaceutical Recent Developments
  31. 6.6 Merck
  32. 6.6.1 Merck Company Information
  33. 6.6.2 Merck Business Overview
  34. 6.6.3 Merck Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Merck Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  36. 6.6.5 Merck Recent Developments
  37. 6.7 Mylan
  38. 6.7.1 Mylan Company Information
  39. 6.7.2 Mylan Business Overview
  40. 6.7.3 Mylan Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Mylan Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  42. 6.7.5 Mylan Recent Developments
  43. 6.8 Roche
  44. 6.8.1 Roche Company Information
  45. 6.8.2 Roche Business Overview
  46. 6.8.3 Roche Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Roche Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  48. 6.8.5 Roche Recent Developments
  49. 6.9 Junshi Biosciences
  50. 6.9.1 Junshi Biosciences Company Information
  51. 6.9.2 Junshi Biosciences Business Overview
  52. 6.9.3 Junshi Biosciences Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Junshi Biosciences Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  54. 6.9.5 Junshi Biosciences Recent Developments
  55. 6.10 Pfizer
  56. 6.10.1 Pfizer Company Information
  57. 6.10.2 Pfizer Business Overview
  58. 6.10.3 Pfizer Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Pfizer Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  60. 6.10.5 Pfizer Recent Developments
  61. 6.11 Henlius
  62. 6.11.1 Henlius Company Information
  63. 6.11.2 Henlius Business Overview
  64. 6.11.3 Henlius Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Henlius Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  66. 6.11.5 Henlius Recent Developments
  67. 6.12 Biotech Pharma
  68. 6.12.1 Biotech Pharma Company Information
  69. 6.12.2 Biotech Pharma Business Overview
  70. 6.12.3 Biotech Pharma Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Biotech Pharma Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  72. 6.12.5 Biotech Pharma Recent Developments
  73. 6.13 Bio-Thera Solutions
  74. 6.13.1 Bio-Thera Solutions Company Information
  75. 6.13.2 Bio-Thera Solutions Business Overview
  76. 6.13.3 Bio-Thera Solutions Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Bio-Thera Solutions Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  78. 6.13.5 Bio-Thera Solutions Recent Developments
  79. 6.14 Amgen
  80. 6.14.1 Amgen Company Information
  81. 6.14.2 Amgen Business Overview
  82. 6.14.3 Amgen Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Amgen Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  84. 6.14.5 Amgen Recent Developments
  85. 6.15 AbbVie
  86. 6.15.1 AbbVie Company Information
  87. 6.15.2 AbbVie Business Overview
  88. 6.15.3 AbbVie Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 AbbVie Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  90. 6.15.5 AbbVie Recent Developments
  91. 6.16 Samsung Bioepis
  92. 6.16.1 Samsung Bioepis Company Information
  93. 6.16.2 Samsung Bioepis Business Overview
  94. 6.16.3 Samsung Bioepis Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Samsung Bioepis Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  96. 6.16.5 Samsung Bioepis Recent Developments
  97. 6.17 Celltrion
  98. 6.17.1 Celltrion Company Information
  99. 6.17.2 Celltrion Business Overview
  100. 6.17.3 Celltrion Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Celltrion Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  102. 6.17.5 Celltrion Recent Developments
  103. 6.18 BristolMyers Squibb
  104. 6.18.1 BristolMyers Squibb Company Information
  105. 6.18.2 BristolMyers Squibb Business Overview
  106. 6.18.3 BristolMyers Squibb Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 BristolMyers Squibb Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  108. 6.18.5 BristolMyers Squibb Recent Developments
  109. 6.19 Biocon
  110. 6.19.1 Biocon Company Information
  111. 6.19.2 Biocon Business Overview
  112. 6.19.3 Biocon Cancer Biosimilar Monoclonal Antibodies Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Biocon Cancer Biosimilar Monoclonal Antibodies Product Portfolio
  114. 6.19.5 Biocon Recent Developments
7 North America
  1. 7.1 North America Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
  3. 7.3 North America Cancer Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
  3. 8.3 Europe Cancer Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
  3. 10.3 South America Cancer Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst